Skip to main content
Premium Trial:

Request an Annual Quote

Story Landis Named NINDS Director; Robert Johnson Joins Spectral Genomics as COO; Exelixis Board Changes

NEW YORK, Aug. 6 (GenomeWeb News) - Story Landis has been appointed director of the National Institute of Neurological Disorders and Stroke, the NIH said today.


Landis, the current scientific director of the NINDS intramural program, will begin to serve as NINDS director September 1. She will oversee an annual budget of $1.5 billion and a staff of over 900 scientists, the NIH said.


Landis has been at NINDS since 1995, when she joined as scientific director. She was also named president-elect of the Society for Neuroscience in 2002. Before that, Landis was chairman of the Department of Neurosciences at Case Western Reserve University School of Medicine. She also previously held a position on the faculty of the Harvard Medical School Department of Neurobiology.

Robert Johnson has been named president and chief operating officer of Spectral Genomics, the Houston-based microarray company said Aug. 4.

Johnson was most recently chief operating officer and chief scientific officer at VitaGen, a cell therapy company. Prior to that, he was senior research director of the gene therapy business unit at Baxter Healthcare, where he worked for 18 years.

Frank McCormick has joined the board of directors at Exelixis, of South San Francisco, and Peter Stadler has resigned from the board, the company said July 31.

McCormick is director of the University of California, San Francisco Comprehensive Cancer Center and a professor of tumor biology and cancer research in the UCSF department of microbiology. Prior to joining UCSF, McCormick was a founder and chief scientific officer at Onyx Pharmaceuticals, and has also held positions of vice president of research at Chiron and vice president of research at Cetus.

Stadler, who is managing director and a co-founder of Artemis Pharmaceuticals, has been a board member of Exelixis since 1998. He is also a former executive of Bayer, and currently serves on the board of the European Biotechnology Association, based in Brussels.

The Scan

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.

Study Points to Synonymous Mutation Effects on E. Coli Enzyme Activity

Researchers in Nature Chemistry saw signs of enzyme activity shifts in the presence of synonymous mutations in a multiscale modeling analysis of three Escherichia coli genes.

Team Outlines Paternal Sample-Free Single-Gene Approach for Non-Invasive Prenatal Screening

With data for nearly 9,200 pregnant individuals, researchers in Genetics in Medicine demonstrate the feasibility of their carrier screening and reflex single-gene non-invasive prenatal screening approach.

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.